{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:05:20Z","timestamp":1780031120797,"version":"3.53.1"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011488","name":"Health and Family Planning Committee of Pudong New Area","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011488","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Sepsis is a life-threatening clinical syndrome defined as acute organ dysfunction caused by a dysregulated host response to infection. At the core of its pathophysiology lies the aberrant activation and dysregulation of the host immune system. The V-domain Ig suppressor of T cell activation (VISTA) is a dual-function immune checkpoint molecule that acts as both a receptor and a ligand, and exerts a pivotal immunoregulatory role in the pathological process of sepsis. Emerging preclinical and clinical evidence indicates that VISTA exerts stage-specific biphasic effects during the progression of sepsis. In the early hyperinflammatory phase, VISTA signaling potentially alleviates the cytokine storm and preserves the integrity of organ barriers; in contrast, during the subsequent immunosuppressive (immune paralysis) phase, aberrant VISTA upregulation may drive the sustained hyporesponsiveness of T cells and the tolerogenic reprogramming of myeloid cells. In this review, we systematically summarize and critically appraise the dynamic expression profiles of VISTA across different stages of sepsis, and synthesize current evidence regarding the multifaceted mechanisms by which VISTA modulates both excessive inflammatory responses and immunosuppression. We further evaluate preclinical studies investigating VISTA-targeted interventions, with a focus on their impacts on survival outcomes, organ injury, and immune cell function. Collectively, this review highlights the central regulatory role of VISTA in the immunoregulatory network of sepsis, and proposes that precision immunomodulatory strategies targeting VISTA hold significant promise as a novel therapeutic approach for patients with sepsis.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1850679","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:53:01Z","timestamp":1780030381000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting VISTA for immunomodulation in sepsis: mechanisms and therapeutic potentials"],"prefix":"10.3389","volume":"17","author":[{"given":"Baoji","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangbin","family":"Yan","sequence":"additional","affiliation":[{"name":"Faculty of Anesthesiology, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Ji","sequence":"additional","affiliation":[{"name":"Faculty of Anesthesiology, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Shanghai East Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhu","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Air Force Medical Center","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulong","family":"Bo","sequence":"additional","affiliation":[{"name":"Faculty of Anesthesiology, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0140-6736(18)30696-2","article-title":"Sepsis and septic shock","volume":"392","author":"Cecconi","year":"2018","journal-title":"Lancet (London England)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2403213","article-title":"Sepsis and septic shock","volume":"391","author":"Meyer","year":"2024","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.10.012","article-title":"The immunology of sepsis","volume":"54","author":"van der Poll","year":"2021","journal-title":"Immunity"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/s13054-023-04762-6","article-title":"Targeting the host response in sepsis: current approaches and future evidence","volume":"27","author":"Bode","year":"2023","journal-title":"Crit Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1172\/JCI82224","article-title":"Sepsis-induced immune dysfunction: can immune therapies reduce mortality","volume":"126","author":"Delano","year":"2016","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.165","article-title":"Advances in the understanding and treatment of sepsis-induced immunosuppression","volume":"14","author":"Venet","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41590-023-01660-5","article-title":"The pathophysiology of sepsis and precision-medicine-based immunotherapy","volume":"25","author":"Giamarellos-Bourboulis","year":"2024","journal-title":"Nat Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13054-024-04964-6","article-title":"Towards personalized medicine: a scoping review of immunotherapy in sepsis","volume":"28","author":"Slim","year":"2024","journal-title":"Crit Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1328667","article-title":"The role of TIM-3 in sepsis: a promising target for immunotherapy","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jss.2022.05.014","article-title":"Tim-3 blockade decreases the apoptosis of CD8+ T cells and reduces the severity of sepsis in mice","volume":"279","author":"Liu","year":"2022","journal-title":"J Surg Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/SHK.0b013e3182168cce","article-title":"Dose-dependent effect of anti-CTLA-4 on survival in sepsis","volume":"36","author":"Inoue","year":"2011","journal-title":"Shock"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-023-01319-5","article-title":"High-dose ascorbic acid potentiates immune modulation through STAT1 phosphorylation inhibition and negative regulation of PD-L1 in experimental sepsis","volume":"32","author":"Zhang","year":"2024","journal-title":"Inflammopharmacology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112413","article-title":"Targeting immune cell checkpoints during sepsis","volume":"18","author":"Patil","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2102477","article-title":"Immune checkpoint inhibitors for the treatment of sepsis: insights from preclinical and clinical development","volume":"31","author":"Rienzo","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-061121-040214","article-title":"Sepsis-induced immunosuppression","volume":"84","author":"Torres","year":"2022","journal-title":"Annu Rev Physiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1715812","article-title":"Immune signatures of sepsis from mild infection to critical illness - a prospective observational study","volume":"16","author":"Snow","year":"2026","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40635-019-0290-x","article-title":"Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis","volume":"8","author":"Busch","year":"2020","journal-title":"Intensive Care Med Exp"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004496","article-title":"Inhibitory immune checkpoint molecule expression in clinical sepsis studies: a systematic review","volume":"48","author":"Busch","year":"2020","journal-title":"Crit Care Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6650329","article-title":"High\u2010affinity anti\u2010VISTA antibody protects against sepsis by inhibition of T lymphocyte apoptosis and suppression of the inflammatory response","volume":"2021","author":"Tao","year":"2021","journal-title":"Mediators Inflammation"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.861670","article-title":"Negative immune checkpoint protein, VISTA, regulates the CD4+ Treg population during sepsis progression to promote acute sepsis recovery and survival","volume":"13","author":"Gray","year":"2022","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiad149","article-title":"VISTA nonredundantly regulates proliferation and CD69low \u03b3\u03b4 T cell accumulation in the intestine in murine sepsis","volume":"115","author":"Gray","year":"2024","journal-title":"J Leukoc Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA is an immune checkpoint molecule for human T cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.12.008","article-title":"VISTA: a mediator of quiescence and a promising target in cancer immunotherapy","volume":"42","author":"Yuan","year":"2021","journal-title":"Trends Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100660","article-title":"Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models","volume":"187","author":"Flies","year":"2011","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.07.073","article-title":"Structure and functional binding epitope of V-domain Ig suppressor of T cell activation","volume":"28","author":"Mehta","year":"2019","journal-title":"Cell Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1908711117","article-title":"Structural insight into T cell coinhibition by PD-1H (VISTA)","volume":"117","author":"Slater","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12935-023-03116-0","article-title":"VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy","volume":"23","author":"Shekari","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1038\/s41467-023-39769-8","article-title":"The checkpoint inhibitor PD-1H\/VISTA controls osteoclast-mediated multiple myeloma bone disease","volume":"14","author":"Fu","year":"2023","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-020-00917-y","article-title":"VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101308","article-title":"VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity","volume":"42","author":"ElTanbouly","year":"2019","journal-title":"Semin Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1194421","article-title":"Immune-checkpoint protein VISTA in allergic, autoimmune disease and transplant rejection","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116100","article-title":"Expression and function of VISTA on myeloid cells","volume":"222","author":"Li","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay0524","article-title":"VISTA is a checkpoint regulator for na\u00efve T cell quiescence and peripheral tolerance","volume":"367","author":"ElTanbouly","year":"2020","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-024-01336-6","article-title":"VISTA-mediated immune evasion in cancer","volume":"56","author":"Zhang","year":"2024","journal-title":"Exp Mol Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1506","article-title":"VISTA regulates the development of protective antitumor immunity","volume":"74","author":"Le Mercier","year":"2014","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41416-025-03013-5","article-title":"Macrophages suppress CD8 + T cell cytotoxic function in triple negative breast cancer via VISTA","volume":"133","author":"Abudula","year":"2025","journal-title":"Br J Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1038\/s41467-024-47256-x","article-title":"VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response","volume":"15","author":"Thisted","year":"2024","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189351","article-title":"VISTA as a context-dependent immune checkpoint: implications for tumor immunity and autoimmune pathogenesis","volume":"1880","author":"Niu","year":"2025","journal-title":"Biochim Et Biophys Acta (BBA) - Rev On Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217581","article-title":"Intracellular and extracellular activities of V-domain Ig-containing suppressor of T cell activation (VISTA) modulated by immunosuppressive factors of tumour microenvironment","volume":"616","author":"Abooali","year":"2025","journal-title":"Cancer Lett"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI74589","article-title":"Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell\u2013mediated immunity","volume":"124","author":"Flies","year":"2014","journal-title":"J Clin Invest"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.015","article-title":"PSGL-1 is an immune checkpoint regulator that promotes T cell exhaustion","volume":"44","author":"Tinoco","year":"2016","journal-title":"Immunity"},{"key":"B48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imm.13001","article-title":"VSIG-3 as a ligand of VISTA inhibits human T-cell function","volume":"156","author":"Wang","year":"2019","journal-title":"Immunology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201601","article-title":"VISTA is an activating receptor in human monocytes","volume":"218","author":"Rogers","year":"2021","journal-title":"J Exp Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.862757","article-title":"Distinct immune stimulatory effects of anti-human VISTA antibodies are determined by Fc-receptor interaction","volume":"13","author":"Mostb\u00f6ck","year":"2022","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01338-y","article-title":"Macrophage-derived VISTA engages with LRIG1 and hinders gut epithelial repair in colitis","volume":"22","author":"Li","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0563-2","article-title":"Acidity changes immunology: a new VISTA pathway","volume":"21","author":"Mahoney","year":"2019","journal-title":"Nat Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1407447111","article-title":"Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity","volume":"111","author":"Wang","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/glia.23517","article-title":"VISTA expression by microglia decreases during inflammation and is differentially regulated in CNS diseases","volume":"66","author":"Borggrewe","year":"2018","journal-title":"Glia"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-020-01968-x","article-title":"Exploring the VISTA of microglia: immune checkpoints in CNS inflammation","volume":"98","author":"Borggrewe","year":"2020","journal-title":"J Mol Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-025-05106-x","article-title":"VISTA alleviates microglia-mediated neuroinflammation after cerebral ischemia\u2013reperfusion injury via regulating ACOD1\/Itaconic acid metabolism","volume":"62","author":"Sun","year":"2025","journal-title":"Mol Neurobiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40478-021-01186-7","article-title":"VISTA regulates microglia homeostasis and myelin phagocytosis, and is associated with MS lesion pathology","volume":"9","author":"Borggrewe","year":"2021","journal-title":"Acta Neuropathol Commun"},{"key":"B58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13054-016-1182-z","article-title":"T cells from patients with Candida sepsis display a suppressive immunophenotype","volume":"20","author":"Spec","year":"2016","journal-title":"Crit Care"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1001\/jama.2011.1829","article-title":"Immunosuppression in patients who die of sepsis and multiple organ failure","volume":"306","author":"Boomer","year":"2011","journal-title":"Jama"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nri3552","article-title":"Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jss.2025.02.001","article-title":"V-domain Ig suppressor of T cell activation expression during hemorrhage or sepsis-induced acute respiratory distress syndrome: insights from a mouse model","volume":"308","author":"Hu","year":"2025","journal-title":"J Surg Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1618135","article-title":"VISTA functions as a protective immune checkpoint in indirect acute respiratory distress syndrome by modulating systemic and compartmentalized inflammation","volume":"16","author":"Hu","year":"2025","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1365240","article-title":"Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors","volume":"15","author":"Iadonato","year":"2024","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.02.007","article-title":"Targeting novel immune checkpoints in the B7-H family: advancing cancer immunotherapy from bench to bedside","volume":"11","author":"Luo","year":"2025","journal-title":"Trends Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04126-3","article-title":"Interpretable inflammation landscape of circulating immune cells","volume":"32","author":"Jim\u00e9nez-Gracia","year":"2026","journal-title":"Nat Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580187","article-title":"VISTA re-programs macrophage biology through the combined regulation of tolerance and anti-inflammatory pathways","volume":"11","author":"ElTanbouly","year":"2020","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2022.104581","article-title":"VISTA as a ligand downregulates LPS-mediated inflammation in macrophages and neutrophils","volume":"379","author":"Vivian Ma","year":"2022","journal-title":"Cell Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.595950","article-title":"VISTA: a target to manage the innate cytokine storm","volume":"11","author":"ElTanbouly","year":"2021","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b21-00616","article-title":"VISTA stimulation of VSIG4-positive macrophages strongly suppresses T cell proliferation via excessive nitric oxide production in sepsis","volume":"44","author":"Lee","year":"2021","journal-title":"Biol Pharm Bull"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-007-0622-2","article-title":"Sepsis-associated delirium","volume":"33","author":"Ebersoldt","year":"2007","journal-title":"Intensive Care Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.183","article-title":"Sepsis-associated encephalopathy","volume":"8","author":"Gofton","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2020.1812384","article-title":"Sepsis-associated encephalopathy and septic encephalitis: an update","volume":"19","author":"Djukic","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B73","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s13054-023-04655-8","article-title":"The spectrum of sepsis-associated encephalopathy: a clinical perspective","volume":"27","author":"Sonneville","year":"2023","journal-title":"Crit Care (London England)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2013.177","article-title":"Imaging in sepsis-associated encephalopathy--insights and opportunities","volume":"9","author":"Stubbs","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.929316","article-title":"Central role of microglia in sepsis-associated encephalopathy: from mechanism to therapy","volume":"13","author":"Yan","year":"2022","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12974-020-1701-3","article-title":"Sepsis-associated encephalopathy: a vicious cycle of immunosuppression","volume":"17","author":"Ren","year":"2020","journal-title":"J Neuroinflamm"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13101453","article-title":"Microglial activation: key players in sepsis-associated encephalopathy","volume":"13","author":"Hu","year":"2023","journal-title":"Brain Sci"},{"key":"B78","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1186\/cc10244","article-title":"Hyperglycaemia and apoptosis of microglial cells in human septic shock","volume":"15","author":"Polito","year":"2011","journal-title":"Crit Care (London England)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105290","article-title":"Microglia reprogram metabolic profiles for phenotype and function changes in central nervous system","volume":"152","author":"Yang","year":"2021","journal-title":"Neurobiol Dis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-024-04572-z","article-title":"Immune checkpoint VISTA negatively regulates microglia glycolysis and activation via TRIM28-mediated ubiquitination of HK2 in sepsis-associated encephalopathy","volume":"62","author":"Xu","year":"2025","journal-title":"Mol Neurobiol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41420-023-01766-7","article-title":"Immune dysregulation in sepsis: experiences, lessons and perspectives","volume":"9","author":"Cao","year":"2023","journal-title":"Cell Death Discov"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113661","article-title":"VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms","volume":"43","author":"Zhang","year":"2024","journal-title":"Cell Rep"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.24175","article-title":"Precision immunotherapy to improve sepsis outcomes: the ImmunoSep randomized clinical trial","volume":"335","author":"Giamarellos-Bourboulis","year":"2026","journal-title":"Jama"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1577105","article-title":"Sepsis-induced immunosuppression: mechanisms, biomarkers and immunotherapy","volume":"16","author":"Gao","year":"2025","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003685","article-title":"Immune checkpoint inhibition in sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559)","volume":"47","author":"Hotchkiss","year":"2019","journal-title":"Crit Care Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98960","article-title":"Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial","volume":"3","author":"Francois","year":"2018","journal-title":"JCI Insight"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940930","article-title":"The neonatal innate immune response to sepsis: checkpoint proteins as novel mediators of this response and as possible therapeutic\/diagnostic levers","volume":"13","author":"Hensler","year":"2022","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1311658","article-title":"A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors","volume":"14","author":"Iadonato","year":"2023","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94308","article-title":"VISTA.COMP \u2014 an engineered checkpoint receptor agonist that potently suppresses T cell\u2013mediated immune responses","volume":"2","author":"Prodeus","year":"2017","journal-title":"JCI Insight"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0117","article-title":"Effective antitumor immunity can be triggered by targeting VISTA in combination with a TLR3-specific adjuvant","volume":"11","author":"Wang","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40779-022-00422-y","article-title":"Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options","volume":"9","author":"Liu","year":"2022","journal-title":"Mil Med Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-025-08110-w","article-title":"Monocyte HLA-DR expression in septic shock patients: insights from a 20-year real-world cohort of 1023 cases","volume":"51","author":"Monneret","year":"2025","journal-title":"Intensive Care Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06854-z","article-title":"Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with (89)Zr-labelled CI-8993","volume":"51","author":"Burvenich","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.624279","article-title":"Immune deregulation in sepsis and septic shock: reversing immune paralysis by targeting PD-1\/PD-L1 pathway","volume":"11","author":"Nakamori","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1850679\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:53:06Z","timestamp":1780030386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1850679\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":94,"alternative-id":["10.3389\/fimmu.2026.1850679"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1850679","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1850679"}}